International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I-CT have been reported.
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas / Merli, M., Frigeni, M., Alric, L., Visco, C., Besson, C., Mannelli, L., Di Rocco, A., Ferrari, A., Farina, L., Pirisi, M., Piazza, F., Loustaud-Ratti, V., Arcari, A., Marino, D., Sica, A., Goldaniga, M., Rusconi, C., Gentile, M., Cencini, E., Benanti, F., et al.. - In: THE ONCOLOGIST. - ISSN 1083-7159. - (2018), pp. 1-10. [10.1634/theoncologist.2018-0331]
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas
Di Rocco, Alice;
2018
Abstract
International guidelines suggest hepatitis C virus (HCV) eradication by direct-acting antivirals (DAAs) after first-line immunochemotherapy (I-CT) in patients with HCV-positive diffuse large B-cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I-CT have been reported.| File | Dimensione | Formato | |
|---|---|---|---|
|
merli_direct-antivirals_2018.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
663.59 kB
Formato
Adobe PDF
|
663.59 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
